article thumbnail

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

XTalks

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Epidiolex contains sesame seed oil, restricting its use for some individuals.

article thumbnail

EverGrain’s Line of Barley-Based Products Scores Upcycled Certification

XTalks

The first-of-its-kind certification , which launched last year, allows food and beverage manufacturers that use upcycled ingredients to place the claim on their packaging. EverGrain’s UFA Certification. EverGrain launched last year with one simple strategy: to utilize barley to its full potential.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both.

article thumbnail

Nanoform sets a new near-term business target for 2021

The Pharma Data

1 Good Manufacturing Practice. Nanoform’s capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Edward Hæggström, CEO. edward.haeggstrom@nanoform.com. 358 29 370 0150. 46 7686 650 11.

article thumbnail

Polymorph profiling with X-ray powder diffraction protects patents and patients

Drug Discovery World

Different polymorphs of the same active pharmaceutical ingredient (API) can have profound effects on solubility, permeability, and bioavailability, as well as manufacturability. In 1998, two years after Norvir’s release to market, a second polymorph created during manufacturing was discovered.

article thumbnail

Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic

Pharmaceutical Technology

Few contract development and manufacturing organizations (CDMOs) are able to provide radiolabeling services as part of a fully integrated pharmaceutical development program. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.

article thumbnail

Solving pharma’s process development challenges one API at a time

Pharmaceutical Technology

During this stage, a team of lab technicians must identify the best way to manufacture the active pharmaceutical ingredient (API) into a suitable dosage form for pilot production. If clinical trials prove successful, that same process should then be scaled to commercial manufacturing.